SAINT-CLOUD, France, June 17, 2024 /PRNewswire/ -- Ethypharm has entered into an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra®, Arganova®, Novastan®, Exembol®), in Europe.

法国SAINT-CLOUD，2024年6月17日/PRNewswire/--Ethypharm已与三菱田边制药公司（MTPC）签订协议，在欧洲收购选择性抗凝血酶药物阿加曲班一水合物（Argatra®，Arganova®，Novastan®，Exembol®）。

Ethypharm, known for its expertise in essential drugs for central nervous system diseases (including severe pain and addiction) and hospital injectables, aims to strengthen its established pharmaceutical business in Europe through internal development, licensing and acquisitions.

Ethypharm以其在中枢神经系统疾病（包括严重疼痛和成瘾）基本药物和医院注射剂方面的专业知识而闻名，旨在通过内部开发、许可和收购来加强其在欧洲的既定制药业务。

In Europe, MTPC first received approval for Argatroban in Sweden in 2004 and the product is currently available as a treatment for heparin-induced thrombocytopenia (HIT) type II in 13 countries, including Germany, the UK, France, Spain and Italy. Heparin induced thrombocytopenia (HIT) type II is a severe condition that carries the risk of fatal thromboembolic complications.

在欧洲，MTPC于2004年在瑞典首次获得阿加曲班的批准，该产品目前可在13个国家（包括德国、英国、法国、西班牙和意大利）用于治疗肝素诱导的II型血小板减少症（HIT）。肝素诱导的II型血小板减少症（HIT）是一种严重的疾病，具有致命的血栓栓塞并发症的风险。

Argatroban is an anticoagulant with a short half-life in the bloodstream that undergoes metabolism in the liver, making it suitable for patients post-surgery and those with kidney disease who may develop HIT type II..

阿加曲班是一种抗凝剂，在肝脏代谢的血流中半衰期短，适用于手术后患者和可能发展为II型HIT的肾脏疾病患者。。

Denis Delval, CEO of Ethypharm, said: 'We are delighted to strengthen our portfolio of essential drugs and bring Argatroban to patients in Europe. Furthermore, we are proud to take over this product following its originator, the well-recognized Mitsubishi Tanabe Pharma Corporation.'

Ethypharm首席执行官丹尼斯·德尔瓦尔（DenisDelval）说：“我们很高兴加强我们的基本药物组合，并将阿加曲班带给欧洲的患者。此外，我们很荣幸继其创始人三菱田边制药公司（Mitsubishi Tanabe Pharma Corporation）之后接管该产品。”

About Ethypharm

关于Ethypharm

Ethypharm is a leading mid-sized international pharmaceutical company, with strong European roots, that manufactures and provides essential drugs, with a focus on hospital care, central nervous system (severe pain and addiction) and internal medicine.

Ethypharm是一家领先的中型国际制药公司，拥有强大的欧洲血统，生产和提供基本药物，专注于医院护理、中枢神经系统（剧烈疼痛和成瘾）和内科。

Ethypharm is committed to improving patients' lives and making a positive impact on society and the environment.

。

Ethypharm has 1,700 employees dedicated to its various pharmaceutical activities, of which 1400 are in industrial operations.

Ethypharm有1700名员工致力于各种制药活动，其中1400人从事工业运营。

The six production sites located in France, the UK, Spain, and China have expertise in injectables and complex oral solid forms.

位于法国、英国、西班牙和中国的六个生产基地拥有注射剂和复杂口服固体形式的专业知识。

With a global presence in 68 countries, the company markets its products directly in Europe and China, and has strategic partnerships in the EMEA, NA, LATAM and APAC markets.

。

Ethypharm works closely with the authorities and healthcare professionals to ensure that its medicines are used appropriately and that patients have access to them.

。

To find out more about Ethypharm, visit http://www.ethypharm.com

To find out more about Ethypharm, visit http://www.ethypharm.com

About Mitsubishi

关于三菱

In Europe, MTPC's subsidiary, Mitsubishi Tanabe Pharma Europe Ltd (hereinafter referred to as 'MTPE,' located in London, United Kingdom), and MTPE's subsidiary, Mitsubishi Tanabe Pharma GmbH (hereinafter referred to as 'MTPD, located in Duesseldorf, Germany), have been actively involved in the marketing and sales of argatroban in United Kingdom and Germany, among other European countries, through their respective networks of partners..

在欧洲，MTPC的子公司Mitsubishi Tanabe Pharma Europe Ltd（以下简称“MTPE”，位于英国伦敦）和MTPE的子公司Mitsubishi Tanabe Pharma GmbH（以下简称“MTPD，位于德国杜塞尔多夫”）通过各自的合作伙伴网络，积极参与argatroban在英国和德国以及其他欧洲国家的营销和销售。。

Mitsubishi Tanabe Pharma Corporation (Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, 'MTPC'), a member of the Mitsubishi Chemical Group remains committed to delivering pharmaceutical products to patients in Europe through MTPE and MTPD, including the continued supply of Radicava® (edaravone), treatment agent for amyotrophic lateral sclerosis, within its European operations, thereby making a meaningful contribution to those facing diseases in the region..

三菱田边制药公司（大阪中央区；代表董事：Akihiro Tsujimura；以下简称“MTPC”）是三菱化学集团的成员，仍然致力于通过MTPE和MTPD向欧洲患者提供药品，包括在其欧洲业务范围内继续供应肌萎缩侧索硬化症治疗剂Radicava®（依达拉奉），从而为该地区面临疾病的患者做出有意义的贡献。。

The company's six production sites are located in France, the UK, Spain and China.

该公司的六个生产基地分别位于法国、英国、西班牙和中国。

About Mitsubishi Tanabe Pharma Group

关于三菱田边制药集团

Mitsubishi Tanabe Pharma Corporation (MTPC), a member of the Mitsubishi Chemical Group, is committed to delivering pharmaceutical products to patients in Europe through Mitsubishi Tanabe Pharma Europe Ltd (MTPE) and Mitsubishi Tanabe Pharma GmbH (MTPD). This includes the continued supply of Radicava® (edaravone), the treatment agent for amyotrophic lateral sclerosis, thereby making a meaningful contribution to those facing diseases in the region.

三菱田边制药公司（MTPC）是三菱化学集团的成员，致力于通过三菱田边制药欧洲有限公司（MTPE）和三菱田边制药有限公司（MTPD）向欧洲患者提供药品。这包括继续供应肌萎缩侧索硬化症的治疗剂Radicava®（依达拉奉），从而为该地区面临疾病的人做出有意义的贡献。

In Europe, MTPE and its subsidiary MTPD have been actively involved in the marketing and sales of argatroban in the UK and Germany, among other European countries, through their respective networks of partners..

在欧洲，MTPE及其子公司MTPD通过各自的合作伙伴网络，积极参与了阿加曲班在英国和德国以及其他欧洲国家的营销和销售。。

Logo - https://mma.prnewswire.com/media/2434581/Ethypharm_Logo.jpg

Logo - https://mma.prnewswire.com/media/2434581/Ethypharm_Logo.jpg

Media contact: Ethypharm: Avril Ponnelle, presse@ethypharm.com

媒体联系人：Ethypharm:Avril Ponnelle，presse@ethypharm.com